Sisram Medical Showcases Impressive Third-Quarter Performance
HONG KONG – Sisram Medical Ltd, known for its innovative contributions to medical aesthetics, has reported robust growth for the third quarter of 2025. The company is renowned for its Energy-Based Devices (EBD), injectables, and complementary solutions, solidifying its position in the global consumer wellness landscape.
Highlights of Revenue Growth
In the most recent quarter, Sisram Medical achieved remarkable double-digit revenue growth compared to the prior year. This increase was mainly fueled by a surge in new orders, reflecting strong demand particularly in dynamic markets. Countries such as China, South Korea, and Thailand played a pivotal role in this development.
Performance of EBD and Injectables
The company's Energy-Based Devices sector continues to excel, highlighted by the success of Alma Harmony, which launched globally in March 2025. This innovative multiplatform showed remarkable sales performance, with substantial new orders flowing in during the quarter. In addition, the Soprano laser devices also performed outstandingly, especially following the recent launch in China, which further boosted order volume.
Innovative Developments in Injectables
Another significant contributor to Sisram's growth has been its injectables division. The strategic expansion of this section has proven vital for the company’s overall performance. A noteworthy milestone was the approval of DAXXIFY from the National Medical Products Administration, marking it as the first botulinum toxin type A product authorized in Mainland China. This innovative product features proprietary Peptide Exchange Technology (PXT), setting a new standard in the industry.
Expanding Global Footprint
Sisram Medical is not just limiting its operations to current markets but is actively pursuing a 'glocalization' strategy. This approach aims to tailor products and sales techniques to meet local market demands effectively. The establishment of a direct sales office in Thailand has already shown promising results, particularly in injectable sales.
Innovative Skincare Products
Recent efforts in the U.S. saw the launch of Universkin by Alma, hailed as the first AI-assisted skincare product line. This innovative approach follows a successful pilot launch, presenting major advancements in aesthetic solutions. Furthermore, the Alma IQ, an intelligent skin analysis platform, has expanded globally, helping practitioners offer advanced medical aesthetic solutions. This reflects Sisram’s commitment to improving clinical outcomes and enriching patient experiences.
CEO Insights on Growth Strategy
Mr. Lior Dayan, the CEO of Sisram and Alma, expressed confidence in the company’s trajectory: "Our third-quarter results reflect the successful execution of our growth strategy. With EBD consistently performing well and our injectables segment entering a vital expansion phase, we are equipped for balanced growth and long-term value creation. We are excited to lead the way in creating intelligent aesthetic solutions that enhance partner value and patient experiences. Our diversified product portfolio positions us ideally to capture emerging opportunities and leverage our leadership in the market for advanced medical aesthetic solutions."
About Sisram Medical Ltd
Sisram Medical Ltd is a recognized leader in the medical aesthetic sector, boasting over 25 years' experience in Energy-Based Devices. The company's dedication to innovation and clinical excellence is underscored by its array of EBD technologies, injectables, diagnostics, and complementary offerings. With a reach spanning more than 110 countries and regions, Sisram is committed to delivering award-winning products that redefine standards in safety, efficacy, and personalized aesthetic care. Majority ownership by Fosun Pharma complements Sisram’s status, as it has been a listed entity on the Hong Kong Stock Exchange since late 2017.
Frequently Asked Questions
What were Sisram Medical's earnings for Q3 2025?
Sisram Medical experienced significant revenue growth in Q3 2025 compared to the previous year, with strong demand driving this performance.
Which regions contributed most to Sisram's growth?
Key markets contributing to Sisram's growth include China, South Korea, and Thailand.
What products drove Sisram's performance in the injectables segment?
The approval and upcoming launch of DAXXIFY have been major factors in expanding Sisram's injectables segment.
How is Sisram Medical expanding its global presence?
Sisram is pursuing a 'glocalization' strategy with initiatives, such as direct sales in Thailand, to effectively localize its offerings.
What is the significance of the Universkin product line?
Universkin by Alma represents a breakthrough in skincare, being the first AI-assisted product line aimed at enhancing the aesthetic treatment experience.
